Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.36 |
| ▸ | GRM5 | P41594 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | MMP13 | P45452 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CTSS | P25774 | 2/20 | 0.34 |
| ▸ | MMP7 | P09237 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | APLNR | P35414 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6673023 | 0.86 | SLC6A7 (0.41) | SLC6A7SIGMAR1GRM5CYP3A4MMP13 | |
| SCHEMBL6806502 | 0.86 | SLC6A7 (0.41) | SLC6A7SIGMAR1GRM5CYP3A4MMP13 | |
| SCHEMBL6671884 | 0.85 | SLC6A7 (0.43) | SLC6A7CTSSSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL6800839 | 0.85 | CYP3A4 (0.38) | SLC6A7CYP3A4MMP13CTSSMMP7 | |
| SCHEMBL6811956 | 0.82 | CYP3A4 (0.42) | SLC6A7SIGMAR1GRM5CYP3A4MMP13 | |
| SCHEMBL6807843 | 0.82 | CYP3A4 (0.42) | SLC6A7SIGMAR1GRM5CYP3A4MMP13 | |
| SCHEMBL6808740 | 0.81 | MMP7 (0.53) | SLC6A7SIGMAR1CYP3A4MMP13CYP2D6 | |
| SCHEMBL6811144 | 0.81 | CYP3A4 (0.35) | SLC6A7SIGMAR1CYP3A4MMP13CYP2D6 | |
| SCHEMBL6671345 | 0.80 | MMP7 (0.51) | SLC6A7CYP3A4MMP13CTSSMMP7 | |
| SCHEMBL6647516 | 0.79 | MMP7 (0.44) | SLC6A7CYP3A4MMP13CTSSMMP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040180901-A1 | Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents | ASTRAZENECA AB (SE) | 2004-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180901-A1 | Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents | MMP13, MMP3, MMP2 | SLC6A7 236/4885SIGMAR1 1197/4885GRM5 950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.